Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Alumis reported a cash position of $502.3 million as of June 30, 2026, which is expected to fund operations into the fourth quarter of 2027. The company released ONWARD3 long-term data showing 54% of patients achieved PASI 100 and 75% achieved PASI 90 at 48 weeks, with an NDA submission for envudeucitinib in plaque psoriasis planned for Q4 2026.
Key figures
- Revenue
- 1.7 million
- Pasi 90
- 75%
- Net loss
- $142.2 million
- Pasi 100
- 54%
- Ga expenses
- $23.4 million
- Rd expenses
- $85.3 million
- Cash position
- $502.3 million
- Impairment loss
- $41.8 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.